Previous 10 | Next 10 |
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Accreditation Committee of the College of American Pathologists (CAP) has accredited its clinical laboratory facility in Pittsburgh. This achiev...
There was no significant difference in decision regret levels among those receiving a low- (Class 1A), intermediate- (Class 1B) or high-risk (Class 2) DecisionDx-UM test result Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that ...
Study finds that DecisionDx-SCC adds clarity and confidence to risk-aligned treatment decisions, independent of clinicopathologic factors and staging Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today a...
Castle also earns national recognition through several Top Workplaces Culture Excellence Awards, including Innovation, Employee Appreciation, Employee Well-Being, Professional Development, Compensation & Benefits, Leadership and Purpose & Values Castle Biosciences, I...
Castle Biosciences, Inc. (CSTL) Q3 2022 Earnings Conference Call November 2, 2022 16:30 ET Company Participants Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs Derek Maetzold - Founder, President and Chief Executive Officer Frank Stokes...
The following slide deck was published by Castle Biosciences, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Castle Biosciences, Inc. 2022 Q3 - Results - Earnings Call Presentation
Castle Biosciences press release ( NASDAQ: CSTL ): Q3 GAAP EPS of -$0.77 beats by $0.11 . Revenue of $37M (+57.4% Y/Y) beats by $2.25M . Further increasing 2022 revenue guidance to $132M-$137M from $130M-$135M. The consensus estimate is $132.25M For f...
Q3 2022 revenue grew by 58% over Q3 2021 to $37.0 million Delivered 12,114 total test reports in Q3 2022, an increase of 57% compared to Q3 2021 Foundational guideposts and three-year financial targets presented at Investor Day in September Further increasing 2...
Castle Biosciences ( NASDAQ: CSTL ) is scheduled to announce Q3 earnings results on Wednesday, November 2nd, after market close. The consensus EPS Estimate is -$0.97 and the consensus Revenue Estimate is $34.75M (+47.9% Y/Y). Over the last 3 months, EPS estimates have ...
Study also shows DecisionDx-SCC is being appropriately utilized by clinicians treating patients with cutaneous squamous cell carcinoma and one or more risk factors, as evidenced by first-year clinical order data Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving he...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...